Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Haroon Saeed

Psychiatry Durham, NC Medical Doctor

NPI 1750597696 CMS profile 1276024

802 Underwood Ave Apt C14, Durham, NC 27701

Open in the dashboard

General payments

$8,477

335 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Haroon Saeed of Durham, NC is reported in the CMS Open Payments database as having received $8,477 across 335 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,834 108
2024 General $1,392 56
2023 General $1,724 69
2022 General $921 43
2021 General $1,363 47
2020 General $242 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Haroon Saeed
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Haroon Saeed were reported at $2,834. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Haroon Saeed Psychiatry median Middle half National median
2019 $0 $184 $59–$605 $163
2020 $242 $119 $36–$372 $114
2021 $1,363 $143 $43–$576 $132
2022 $921 $153 $50–$590 $149
2023 $1,724 $170 $56–$651 $160
2024 $1,392 $179 $57–$673 $164
2025 $2,834 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Otsuka America Pharmaceutical, Inc. $1,890 87 payments
  2. Alkermes, Inc. $1,851 61 payments
  3. Neurocrine Biosciences, Inc. $1,121 46 payments
  4. Janssen Pharmaceuticals, Inc $944 38 payments
  5. Lundbeck LLC $939 37 payments
  6. E.R. Squibb & Sons, L.L.C. $639 15 payments
  7. Teva Pharmaceuticals USA, Inc. $638 35 payments
  8. BioXcel Therapeutics, Inc. $306 9 payments
  9. ITI, Inc. $66 3 payments
  10. Luye Pharma (USA) Ltd. $45 2 payments
  11. Other $39 2 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $8,477 335 payments
Products named General payments · program years 2020–2025
  1. ABILIFY MAINTENA $1,510 68 payments
  2. ABILIFY ASIMTUFII $1,330 57 payments
  3. INGREZZA $998 40 payments
  4. INVEGA SUSTENNA $912 37 payments
  5. LYBALVI $874 30 payments
  6. ARISTADA Cns $856 29 payments
  7. ARISTADA Cns $856 29 payments
  8. ARISTADA Cns $813 27 payments
  9. ARISTADA Cns $813 27 payments
  10. VIVITROL $670 27 payments
  11. Other $4,047 137 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$27,712

Medicare's payments for the services billed

Medicare patients

36

Average age 48

Services billed

290

16 women, 20 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 61%
Diabetes 39%
Atrial fibrillation 0%
Cancer 0%
Osteoporosis 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INGREZZA
  • Neurocrine Biosciences, Inc. $313
$313 — —
ABILIFY ASIMTUFII
  • Lundbeck LLC $153
  • Otsuka America Pharmaceutical, Inc. $123
$276 — —
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $242
$242 — —
VIVITROL
  • Alkermes, Inc. $143
$143 — —
ARISTADA
  • Alkermes, Inc. $113
$113 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

335 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record